Thursday, October 15, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 20, 2026

Crypto Casino No Deposit Bonus 2026: BitStarz Launches “BIGWIN50” Code with Free Spins & Instant Crypto Payouts

View original at globenewswire.com
Crypto Casino No Deposit Bonus 2026: BitStarz Launches “BIGWIN50” Code with Free Spins & Instant Crypto Payouts New York City, NY, March 20, 2026 (GLOBE NEWSWIRE) -- As interest in crypto casino no deposit bonus offers continues to rise, many players are becoming more cautious about hidden wagering requirements and slo…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Withdrawal times can be completed in under 10 minutes for crypto payouts

    60% confidence

  • Platforms that maintain clear rules, manageable conditions, and efficient payout handling are likely to remain relevant as user expectations continue to evolve

    60% confidence

  • Interest in crypto casino no deposit bonus offers continues to rise

    60% confidence

  • Crypto casinos with no deposit bonuses are focusing on clear bonus terms, moderate wagering, and faster payouts in 2026

    60% confidence

Data points we hold from this source

BitStarz Casino · level up prize pool70000 USD
BitStarz Casino · tables tournament prize10000 EUR
BitStarz Casino · slot wars weekly prize10000 EUR
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com